Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Non-small Cell Lung Cancer Metastatic
- Interventions
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 642
- Registration Number
- NCT01966003
- Locations
- 🇧🇬
Research Site, Ruse, Bulgaria
Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 74
- Registration Number
- NCT01953341
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
Phase 2
Completed
- Conditions
- Migraine
- Interventions
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 483
- Registration Number
- NCT01952574
- Locations
- 🇸🇪
Research Site, Vällingby, Sweden
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
Phase 3
Completed
- Conditions
- Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
- Interventions
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 409
- Registration Number
- NCT01953328
- Locations
- 🇯🇵
Research Site, Toshima-ku, Tokyo, Japan
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
Phase 1
Completed
- Conditions
- Solid TumorsHematologic MalignanciesHepatic Impairment
- Interventions
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 46
- Registration Number
- NCT01949545
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Duke Cancer Institute, Durham, North Carolina, United States
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
Phase 1
Completed
- Conditions
- Relapsed Multiple MyelomaEnd-stage Renal Disease
- Interventions
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 26
- Registration Number
- NCT01949532
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸North Shore-LIJ Health System/Center for Advanced Medicine - North Shore University Hospital, Lake Success, New York, United States
Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)
Terminated
- Conditions
- Urea Cycle Disorder
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 203
- Registration Number
- NCT01948427
- Locations
- 🇺🇸
United BioSource Corporation, Blue Bell, Pennsylvania, United States
Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 158
- Registration Number
- NCT01932970
- Locations
- 🇺🇸
Research Site, Hampton, Virginia, United States
Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
Phase 4
Terminated
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- Interventions
- Biological: Etanercept
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 90
- Registration Number
- NCT01927757
- Locations
- 🇵🇷
Research Site, Caguas, Puerto Rico
A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2016-12-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 70
- Registration Number
- NCT01928368
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath